Among the array of PBM policies under Congressional consideration is one known as “delinking,” which would ban PBM compensation in Medicare Part D from being tied to a drug manufacturer’s list price. The risk of government intervention into the operations of PBMs is not limited to Part D. Some lawmakers have proposed delinking PBM compensation from price across all PBM lines of business, including commercial insurance.
Pharmaceutical Care
Management Association
325 7th Street, NW
Washington, DC 20004
Main: 202.756.5700
©2024 PCMA. All Rights Reserved.